Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone781-345-9001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$89.79 million
Profitability
Miscellaneous
Employees262
Next Earnings Date5/1/2019 (Confirmed)
OptionableNot Optionable
ConforMIS (NASDAQ:CFMS) Frequently Asked Questions
What is ConforMIS's stock symbol?
ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."
How were ConforMIS's earnings last quarter?
ConforMIS Inc (NASDAQ:CFMS) released its quarterly earnings data on Wednesday, February, 6th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The medical instruments supplier had revenue of $22.05 million for the quarter, compared to analyst estimates of $21.45 million. ConforMIS had a negative net margin of 48.30% and a negative return on equity of 91.73%. View ConforMIS's Earnings History.
When is ConforMIS's next earnings date?
What price target have analysts set for CFMS?
5 analysts have issued twelve-month target prices for ConforMIS's shares. Their predictions range from $2.50 to $3.50. On average, they expect ConforMIS's share price to reach $3.00 in the next year. This suggests a possible upside of 23.0% from the stock's current price. View Analyst Price Targets for ConforMIS.
What is the consensus analysts' recommendation for ConforMIS?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.
What are Wall Street analysts saying about ConforMIS stock?
Here are some recent quotes from research analysts about ConforMIS stock:
- 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (4/10/2019)
- 2. BTIG Research analysts commented, "Ongoing OUS Headwinds While CFMS 2Q18 results were a bit below our expectations (rev. of $19.1M (+3% Y/Y,+2% xFx) vs. BTIG/Consensus of $19.3M/$19.4M respectively, product rev. increased Y/Y for the first time since 1Q17, growing 5% to $18.0M. Mgmt. is making progress on US commercialization (albeit slower than investors will prefer). OUS continues to be challenged in Germany but mgmt. noted recent OUS sales leadership hires that may open up a few countries in 2H18. Mgmt. commentary on payor acceptance of CFMS products indicates increasing positive traction amongst some payers but CFMS is still not where it wants to be on rep growth, which missed the 20% growth target slightly. On the call, mgmt. announced plans to reduce OpEx while shuffling its product pipeline around." (8/2/2018)
Has ConforMIS been receiving favorable news coverage?
Media headlines about CFMS stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ConforMIS earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Are investors shorting ConforMIS?
ConforMIS saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 3,033,592 shares, an increase of 105.4% from the March 15th total of 1,476,806 shares. Based on an average daily trading volume, of 2,812,128 shares, the short-interest ratio is currently 1.1 days. Approximately 5.2% of the shares of the company are sold short. View ConforMIS's Current Options Chain.
Who are some of ConforMIS's key competitors?
Some companies that are related to ConforMIS include Establishment Labs (ESTA), RTI Surgical (RTIX), Invacare (IVC), Sientra (SIEN), Lakeland Industries (LAKE), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), NanoVibronix (NAOV), Bionik Laboratories (BNKL), Precision Therapeutics (AIPT), Rewalk Robotics (RWLK), Wound Management Technologies (WNDM), Allied Healthcare Products (AHPI), Avitar (AVTI) and Halyard Health (HYH).
What other stocks do shareholders of ConforMIS own?
Who are ConforMIS's key executives?
ConforMIS's management team includes the folowing people:
- Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
- Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
- Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
- Mr. Ed Kilgallen, VP of Operations
- Ms. Lisa M. Donnelly, Sr. VP of Global Marketing
When did ConforMIS IPO?
(CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
Who are ConforMIS's major shareholders?
ConforMIS's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tibra Equities Europe Ltd (0.19%), CAPROCK Group Inc. (0.12%) and Larson Financial Group LLC (0.04%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.
Which major investors are buying ConforMIS stock?
How do I buy shares of ConforMIS?
Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ConforMIS's stock price today?
One share of CFMS stock can currently be purchased for approximately $2.44.
How big of a company is ConforMIS?
ConforMIS has a market capitalization of $165.72 million and generates $89.79 million in revenue each year. The medical instruments supplier earns $-43,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. ConforMIS employs 262 workers across the globe.
What is ConforMIS's official website?
How can I contact ConforMIS?
ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]
MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
